Biliary Atresia Market

Biliary Atresia Market Summary

The Biliary Atresia market size is expected to grow steadily at a CAGR of 7.7% (2024–2034), driven by rising incidence, better diagnostics, and wider treatment adoption. In 2023, there were about 609 incident cases of Biliary Atresia in the 7MM, with the US accounting for 56%, EU4 and the UK for 28%, and Japan for 16%. However, treatment remains limited, as no approved drug therapies exist, with reliance on surgeries like the Kasai procedure and liver transplantation. To address unmet needs, several promising drugs such as odevixibat and obeticholic acid are under development.

DelveInsight’s report, “Biliary Atresia Market Insights, Epidemiology, and Market Forecast – 2034”, offers a comprehensive analysis of the disorder, covering historical data, projected epidemiology, and market dynamics across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The Biliary Atresia market is emerging as a significant segment within the healthcare industry, primarily fueled by the rising prevalence of the condition and ongoing advancements in treatment approaches. It spans multiple therapeutic areas, including adjunctive therapies, antipsychotics, and innovative treatment options currently under development. The report highlights existing treatment practices, investigational drugs, therapy-wise market share, and the estimated market size from 2020 through 2034, segmented across the seven major markets. In addition, it explores treatment algorithms, key market drivers and restraints, unmet clinical needs, and potential growth opportunities, offering an in-depth outlook on the future of the Biliary Atresia market.

Discover Key Insights into the Biliary Atresia Market with DelveInsight’s In-Depth Report @ Biliary Atresia Market Outlook

Key Takeaways from the Biliary Atresia Market Report

• In March 2025, Mirum Pharmaceuticals, Inc announced results of a Randomized Double-Blind Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Maralixibat in the Treatment of Participants with Cholestatic Pruritus
• In November 2024, Intercept Pharmaceuticals announced results of a Randomized, Double-blind, Placebo-controlled, Phase 2/3 Study to Assess the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Obeticholic Acid Compared to Placebo in Pediatric Subjects With Biliary Atresia, Post-hepatoportoenterostomy
• In October 2024:- Mirum Pharmaceuticals Inc.- The purpose of this study is to determine whether the investigational treatment (maralixibat) is safe and effective in pediatric and adult participants who have cholestatic liver disease with pruritus that has been refractory to other therapies, and who have no other treatment options.
• In October 2024:- Albireo, an Ipsen Company- A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Odevixibat (A4250) in Children With Biliary Atresia Who Have Undergone a Kasai Hepatoportoenterostomy. Double-blind, randomized, placebo-controlled, Phase 3 study to investigate the efficacy and safety of odevixibat compared to placebo in children with biliary atresia who have undergone a Kasai hepatoportoenterostomy.
• According to DelveInsight’s epidemiology model, in 2023, the Incident cases of biliary atresia in the US was found to be approximately 338, these case are expected to increase by 2034.
• In 2023, there were nearly 17 cases of Type I, 7 cases of Type II and 315 cases for Type III. Our estimates suggest that these cases will change during the forecast period (2024-2034).
• In 2023, Germany saw approximately 34 cases of biliary atresia, with around 17 cases in males and 18 in females.
• In 2023, in the UK there were approximately 19 cases of biliary atresia in males and 25 cases in females. Assessments as per DelveInsight’s analysts show that the overall cases of biliary atresia in both the genders is subjected to decrease in the coming years directly attributed to the country population that is decreasing by 2034, in males and females, respectively.
• In 2023, in Japan there were 11 cases of Type I and 2 cases of Type II. Assessments as per DelveInsight’s analysts show that the overall incidence of biliary atresia is maximum for type III with 80 cases.
• The leading Biliary Atresia Companies working in the market include Mirium Pharmaceuticals, Albireo, Intercept Pharmaceuticals, Ipsen and others.
• Promising Biliary Atresia Therapies in the various stages of development include BYLVAY, LIVMARLI, and others.

Biliary Atresia Overview

Biliary Atresia is a rare but serious liver condition that affects infants, characterized by the blockage or absence of bile ducts. Biliary Atresia prevents bile from flowing from the liver to the gallbladder, leading to liver damage and scarring. Biliary Atresia symptoms typically appear within the first few weeks of life and may include jaundice, dark urine, pale stools, and poor weight gain. Biliary Atresia diagnosis involves a combination of blood tests, imaging studies, and sometimes a liver biopsy. Biliary Atresia treatment primarily includes surgery, known as the Kasai procedure, which aims to restore bile flow. Biliary Atresia surgery is most effective when performed early, ideally within two months of birth. Biliary Atresia prognosis improves with timely intervention, though many children may eventually require a liver transplant. Biliary Atresia research is ongoing to better understand its causes and develop more effective treatments. Biliary Atresia awareness is crucial for early detection and management. Biliary Atresia support groups and medical teams play a key role in helping families navigate the condition. Biliary Atresia outcomes vary, but early diagnosis and appropriate care can significantly improve quality of life. Biliary Atresia remains a leading cause of pediatric liver transplants worldwide.

Stay ahead in the Biliary Atresia Therapeutics Market with DelveInsight’s Strategic Report @ Biliary Atresia Treatment Market

Biliary Atresia Epidemiology Segmentation in the 7MM

• Total Biliary Atresia Incident cases
• Biliary Atresia Type-specific cases
• Biliary Atresia Gender-specific cases
• Biliary Atresia Treated cases

Download the report to understand which factors are driving Biliary Atresia epidemiology trends @ Biliary Atresia Patient Population and Prevalence

Biliary Atresia Market Outlook

Biliary Atresia (BA) is defined by progressive fibro-proliferative obliteration of the biliary tree, ultimately leading to hepatic fibrosis, cirrhosis, and end-stage liver disease. Management is primarily surgical, typically involving two stages: an early Hepatoportoenterostomy (Kasai procedure) to re-establish bile flow, followed by liver transplantation in cases of failed HPE or advanced cirrhosis. BA remains the leading pediatric indication for liver transplantation.

Postoperative management includes choleretic agents (e.g., ursodeoxycholic acid) to enhance bile flow, though their efficacy is not fully validated. Supportive care involves nutritional optimization, fat-soluble vitamin supplementation, prevention of cholangitis, and management of portal hypertension. Medium-chain triglyceride (MCT)-based nutrition is preferred due to its high caloric density and efficient absorption in cholestasis.

Overall, treatment is multidimensional, combining surgical intervention with medical and nutritional strategies aimed at delaying disease progression, minimizing complications, and improving long-term outcomes.

Biliary Atresia Market Drivers

• Rising Incidence and Prevalence: Increasing number of diagnosed cases across the US, EU4+UK, and Japan is driving demand for effective treatments.
• Advancements in Diagnostics: Improved neonatal screening and imaging techniques are enabling earlier detection, which supports better outcomes and increases treatment uptake.
• Surgical Innovation and Transplantation Outcomes: Refinements in the Kasai procedure and advancements in pediatric liver transplantation have improved survival rates, creating a more structured treatment pathway.
• Emerging Drug Pipeline: Development of novel therapeutics (e.g., odevixibat, obeticholic acid) targeting cholestasis and liver damage is expected to expand treatment options.
• Rising Awareness and Research Funding: Increasing focus from research organizations, rare disease networks, and healthcare systems is supporting clinical trials and patient management.

Biliary Atresia Market Barriers

• Lack of Approved Pharmacological Therapies: No FDA/EMA-approved drugs exist for BA, leaving surgery as the primary treatment modality.
• High Dependence on Invasive Procedures: Reliance on the Kasai operation and liver transplantation carries risks, high costs, and limited donor availability.
• Variable Treatment Outcomes: Success of HPE depends on timing and surgical expertise, with significant variability in long-term survival and quality of life.
• Limited Awareness in Low-Incidence Regions: Delayed diagnosis due to poor awareness among healthcare providers and parents reduces the effectiveness of surgical interventions.
• Regulatory and Developmental Challenges: Small patient population and rare disease designation hinder large-scale clinical trials and delay drug development.

Get In-Depth Knowledge on Biliary Atresia Market Trends and Forecasts with DelveInsight @ Biliary Atresia Market Drynamics and Trends

Biliary Atresia Emerging Drugs

• BYLVAY (odevixibat): Ipsen

Odevixibat (A-4250), a potent and selective inhibitor of the ileal bile acid transporter (IBAT), also known as apical sodium-dependent bile acid transporter (ASBT), acts locally in the gut, and has minimal systemic exposure at the therapeutic dose. IBAT initiates the transport of bile acids, which flow through the portal vein back to the liver in a process known as enterohepatic circulation. Approximately 95% of bile acids are recirculated via the IBAT to the liver. Accordingly, a product capable of inhibiting the IBAT could lead to a reduction in bile acids returning to the liver and may represent a promising approach for treating cholestatic liver diseases. Odevixibat is being developed by Ipsen that completed acquisition of Albireo, expanding the scope of its rare disease portfolio.

• Obeticholic Acid: Intercept Pharmaceuticals

Obeticholic acid (OCA) is a first-in-class agonist that selectively binds to the farnesoid X receptor (FXR), a nuclear receptor expressed in the liver and intestine. FXR is a key regulator of bile acid, inflammatory, fibrotic, and metabolic pathways. FXR activation decreases the intracellular hepatocyte concentrations of bile acids by suppressing de novo synthesis from cholesterol as well as by increased transport of bile acids out of the hepatocytes. These mechanisms limit the overall size of the circulating bile acid pool while promoting choleresis, thus reducing hepatic exposure to bile acids.

Unlock Strategic Insights with DelveInsight’s Comprehensive Biliary Atresia Market Report @ Biliary Atresia Clinical Trials and FDA Approvals

Scope of the Biliary Atresia Market Report

• Coverage- 7MM
• Biliary Atresia Companies- Mirum Pharmaceuticals (NASDAQ: MIRM), Albireo Pharma (NASDAQ: ALBO), Intercept Pharmaceuticals (NASDAQ: ICPT), Ipsen (EPA: IPN), and others.
• Biliary Atresia Therapies- BYLVAY, LIVMARLI, and others.
• Biliary Atresia Market Dynamics: Biliary Atresia Market Drivers and Barriers
• Biliary Atresia Market Access and Reimbursement, Unmet Needs and Future Perspectives

Table of Content

1 Key Insights

2 Report Introduction

3 Market Overview at a Glance

4 Epidemiology and Market Forecast Methodology

5 Executive Summary

6 Key Events

7 Disease Background and Overview

8 Patient Journey

9 Epidemiology and Patient Population

10 Emerging Drugs

11 Biliary atresia: Market Analysis

12 Key Opinion Leaders’ Views

13 SWOT Analysis

14 Unmet Needs

15 Market Access and Reimbursement

16 Appendix

17 DelveInsight Capabilities

18 Disclaimer

19 About DelveInsight

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/conference-coverage-services